MIPEP

Across TCGA pan-cancer cohorts, MIPEP mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MIPEP data layer compared with 22 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher MIPEP mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MIPEP expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

LSCC, PDAC, and LUAD are the cancer types where MIPEP mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	II,III,IV	0.882	0.663	.006	8	view →
PDAC	OS	Quartile	III,IV	0.351	0.968	.004	6	view →
LUAD	OS	Quartile	III,IV	0.879	0.278	.008	5	view →
CCRCC	DFS	Quartile	III,IV	0.222	0.887	.038	4	view →
HNSC	DFS	Tertile	III,IV	0.896	1.000	.019	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MIPEP–LSCC (DFS)

Open the LSCC breakdown →